Genocea Biosciences (GNCA) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Genocea Reports First Quarter 2016 Financial Results
May 5, 2016 8:06 AM EDTÂ - Positive 12-month efficacy data for GEN-003 for genital herpes strengthens value proposition -
- Multiple 2016 clinical milestones for GEN-003 anticipated -
CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported corporate highlights and financial results for the first quarter ended March 31, 2016.
"Our positive GEN-003 Phase 2 12-month efficacy data suggests that annual treatment with GEN-003 may offer genital herpes patients similar benefits to a full year of daily administration of... More
